Researchers uncover potential non-opioid treatment for chronic pain
A new approach to treating neuropathic pain is making a key step forward thanks to researchers at The University of Texas at Austin.
Jan 30, 2024
0
74
A new approach to treating neuropathic pain is making a key step forward thanks to researchers at The University of Texas at Austin.
Jan 30, 2024
0
74
A common test used to decide whether breast cancer patients should receive chemotherapy may be making bad recommendations for some Black women, leading them to forgo chemotherapy when it might have helped, according to new ...
Jan 29, 2024
0
0
For patients with radically resected, stage II to IV colorectal cancer (CRC), circulating tumor (ct)DNA-based detection of molecular residual disease (MRD) in response to adjuvant chemotherapy (ACT) is prognostic of outcomes, ...
Jan 29, 2024
0
0
Tisch Cancer Institute researchers have discovered that a certain type of chemotherapy improves the immune system's ability to fight off bladder cancer, particularly when combined with immunotherapy.
Jan 26, 2024
0
15
Researchers at Karolinska Institutet and SciLifeLab demonstrate in a new study published in iScience how they can identify substances that can deactivate an enzyme responsible for chemotherapy resistance in cancer cells. ...
Jan 18, 2024
0
27
For patients whose breast cancer converted from lymph node-positive to lymph node-negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation (RNI) did not increase the risk of disease recurrence ...
Jan 15, 2024
0
0
An international clinical trial of a treatment for advanced urothelial cancer has found a new dual therapy can nearly double patients' life expectancy.
Jan 9, 2024
0
0
A phase III LIBRETTO-431 multicenter study has evaluated the efficacy and safety of selpercatinib compared to control treatment, which consisted of platinum-based chemotherapy associated or not with pembrolizumab (immune ...
Jan 5, 2024
0
1
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood ...
Jan 4, 2024
0
0
A new review paper titled "Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in Brazil: Balancing efficacy, safety, and tolerability" has been published in Oncotarget.
Dec 20, 2023
0
0